ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2015
Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy.
Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Genetic Concordance in Primary Cutaneous Melanoma and Matched Metastasis: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- BRAF V600E Mutation in Malignant Melanoma-A Romanian Research Experience.Medicina (Kaunas, Lithuania) · 2024Article
- Artificial Intelligence to Predict the BRAF V595E Mutation in Canine Urinary Bladder Urothelial Carcinomas.Animals : an open access journal from MDPI · 2023Article
- Review
- Heterogeneity in Melanoma.Cancers · 2022Review
- Review
- Recurrence of mucosal melanoma in Li-Fraumeni syndrome: A follow-up of an index case.JAAD case reports · 2021Article
- BRAF Heterogeneity in Melanoma.Current treatment options in oncology · 2021Review
- Concordance and Discordance Rates of V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (JMA journal · 2020Article
- Identification of robust reference genes for studies of gene expression in FFPE melanoma samples and melanoma cell lines.Melanoma research · 2020Article
- Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases.Acta dermato-venereologica · 2020Article
- Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma.BMC cancer · 2019Article
- Adjuvant Therapy for Melanoma.Current treatment options in oncology · 2019Review
- Article
- Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- Updates in adjuvant systemic therapy for melanoma.Journal of surgical oncology · 2019Review
- Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Review
- Intratumor and Intertumor Heterogeneity in Melanoma.Translational oncology · 2017Review
- Molecular genetic and immunotherapeutic targets in metastatic melanoma.Virchows Archiv : an international journal of pathology · 2017Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic targeted molecular therapy, in the form of a selective BRAF inhibitor with or without a MEK inhibitor, is a standard treatment for patients with BRAF V600 mutation-positive melanoma with unresectable stage III and IV disease. Patients with BRAF mutation-negative primary tumors may manifest BRAF mutation-positive metastatic disease. It is unclear whether all metastatic lesions carry the same BRAF mutation status found in the primary tumor and if discordancy exists, in what frequency it occurs. Primary and matched metastatic lesions in 25 melanoma patients were tested for the BRAF V600E/Ec, V600K, V600D, and V600R mutations using a BRAF RGQ PCR kit (Qiagen). Four patients (16%) had discrepancies between their primary and metastatic melanoma BRAF status. Of these patients, 2 (8%) had BRAF mutation-positive primary melanomas with BRAF mutation-negative metastatic lesions and 2 (8%) patient had BRAF mutation-negative melanoma with a BRAF mutation-positive metastatic lesion. In summary, discordancy of BRAF mutation status is not an infrequent finding between primary and metastatic melanoma. It may be prudent in previously negative patients to determine BRAF mutation status of new metastatic tumors for proper allocation of BRAF inhibitor therapy. Discordant BRAF status may have a role in the varying patterns of response and inevitable resistance seen with BRAF inhibitor therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.